simplyStocks
Explore all companies →
Globus Medical, Inc.
GMED · NYSEHealthcare
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
Inputs &supplyAPIs, bioprocess, compone…Discovery &trialsR&D, partners, regulatorsManufacturingDrug substance, fill-fini…ProductsMedicines, therapies, dev…Payers &distributionWholesalers, PBMs, health…Providers &patientsHospitals, surgeons, pati…TITitanium & PEEK stockCMPPrecision component vendorsBIOTissue banks & biologicsGRGlobus R&DSCSurgeon co-developmentF/NBFDA / notified bodiesIMIn-house manufacturingEAEnabling-tech assemblyGMEDGlobus MedicalMDTMedtronicSYKStrykerZBHZimmer BiometJNJJ&J MedTech (DePuy Synthes)SR&DSales reps & distributorsGPOGPOs & hospital purchasingHOSPHospitals & surgery centersSURGSpine & orthopedic surgeonsPATPatients
Company details
Market cap
$11B
P/E ratio
19×
Div yield
EPS (TTM)
$4.29
Profit margin
18%
Rev. growth
+17%
Revenue
$2.9B
Free cash flow
$0.6B
In plain English
Globus Medical is a musculoskeletal-solutions company — spinal implants, trauma and joint hardware, biologics and surgical robots (ExcelsiusGPS). It is unusually vertically integrated, designing and machining most of its own titanium and PEEK implants in-house. Two back-to-back deals reshaped it: the ~$3.1B all-stock NuVasive merger (2023) made it the clear #2 in spine behind Medtronic, and the ~$250M Nevro buy (2025) pushed it into neuromodulation for chronic pain.
In simple terms
What Globus Medical, Inc. really sells
Globus Medical is a musculoskeletal-solutions company — spinal implants, trauma and joint hardware, biologics and surgical robots (ExcelsiusGPS). It is unusually vertically integrated, designing and machining most of its own titanium and PEEK implants in-house. Two back-to-back deals reshaped it: the ~$3.1B all-stock NuVasive merger (2023) made it the clear #2 in spine behind Medtronic, and the ~$250M Nevro buy (2025) pushed it into neuromodulation for chronic pain.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
Moderate
SteadierMore speculative
Why this rating?